{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:37:04Z","timestamp":1784230624613,"version":"3.55.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001009","name":"Sanofi-Aventis and Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001009","name":"Bristol-Myers Squibb and Pfize","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001009","name":"Bristol-Myers Squibb and Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003748","name":"Swedish Society for Medical Research","doi-asserted-by":"publisher","award":["S17\u20130133"],"award-info":[{"award-number":["S17\u20130133"]}],"id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Swedish Heart-Lung Foundation","doi-asserted-by":"publisher","award":["20200722"],"award-info":[{"award-number":["20200722"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005423","name":"Uppsala University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Several biomarkers are associated with clinical outcomes in patients with atrial fibrillation (AF), but a causal relationship has not been established. This study aimed to evaluate angiopoietin-2, a novel candidate biomarker of endothelial inflammation and vascular remodelling, in patients with AF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Angiopoietin-2 was measured in plasma obtained from patients with AF treated with aspirin monotherapy (exploration cohort, n = 2987) or with oral anticoagulation (validation cohort, n = 13 079). Regression models were built to assess the associations between angiopoietin-2, clinical characteristics, and outcomes. In both cohorts, plasma angiopoietin-2 was independently associated with AF on the baseline electrocardiogram and persistent\/permanent AF, age, history of heart failure, female sex, tobacco use\/smoking, body mass index, renal dysfunction, diabetes, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Angiopoietin-2 was independently associated with subsequent hospitalization for heart failure after adjusting for age, creatinine, and clinical characteristics in the exploration cohort [c-index 0.79, 95% confidence interval (CI) 0.75\u20130.82; third vs. first quartile, hazard ratio (HR) 1.74, 95% CI 1.26\u20132.41] and in the validation cohort (c-index 0.76, 95% CI 0.74\u20130.78; HR 1.58, 95% CI 1.37\u20131.82). In both cohorts, the association persisted when also adjusting for NT-proBNP (P \u2264 0.001). In full multivariable models also adjusted for NT-proBNP, angiopoietin-2 did not show statistically significant associations with ischaemic stroke, cardiovascular and all-cause death, or major bleeding that were consistent across the two cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with AF, plasma levels of angiopoietin-2 were independently associated with subsequent hospitalization for heart failure and provided incremental prognostic value to clinical risk factors and NT-proBNP.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euad200","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T12:26:11Z","timestamp":1689423971000},"source":"Crossref","is-referenced-by-count":13,"title":["Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2555-1266","authenticated-orcid":false,"given":"Alexander P","family":"Benz","sequence":"first","affiliation":[{"name":"Population Health Research Institute, McMaster University , 237 Barton St. E., Hamilton, Ontario L8L 2X2 , Canada"},{"name":"Department of Cardiology, University Medical Center Mainz, Johannes Gutenberg-University , Langenbeckstr. 1, Mainz 55131 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7420-743X","authenticated-orcid":false,"given":"Ziad","family":"Hijazi","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University , Uppsala , Sweden"},{"name":"Department of Medical Sciences, Cardiology, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6473-8798","authenticated-orcid":false,"given":"Johan","family":"Lindb\u00e4ck","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J","family":"Connolly","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , 237 Barton St. E., Hamilton, Ontario L8L 2X2 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4126-1285","authenticated-orcid":false,"given":"John W","family":"Eikelboom","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , 237 Barton St. E., Hamilton, Ontario L8L 2X2 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8744-7152","authenticated-orcid":false,"given":"Peter","family":"Kastner","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9838-8087","authenticated-orcid":false,"given":"Andr\u00e9","family":"Ziegler","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1444-2462","authenticated-orcid":false,"given":"John H","family":"Alexander","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0045-3291","authenticated-orcid":false,"given":"Christopher B","family":"Granger","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-4961","authenticated-orcid":false,"given":"Renato D","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-3921","authenticated-orcid":false,"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University , Uppsala , Sweden"},{"name":"Department of Medical Sciences, Cardiology, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3955-5671","authenticated-orcid":false,"given":"Agneta","family":"Siegbahn","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University , Uppsala , Sweden"},{"name":"Department of Medical Sciences, Clinical Chemistry, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-6531","authenticated-orcid":false,"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University , Uppsala , Sweden"},{"name":"Department of Medical Sciences, Cardiology, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"2023072022174477700_euad200-B1","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"2023072022174477700_euad200-B2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2023072022174477700_euad200-B3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1161\/CIRCULATIONAHA.113.006286","article-title":"High-sensitivity troponin i for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"key":"2023072022174477700_euad200-B4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jacc.2013.07.093","article-title":"High-sensitivity troponin t and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin","volume":"63","author":"Hijazi","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023072022174477700_euad200-B5","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.jacc.2012.11.082","article-title":"N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for the Prevention of Stroke in Subjects with Atrial Fibrillation)","volume":"61","author":"Hijazi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2023072022174477700_euad200-B6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2017.06.001","article-title":"Growth\u2013differentiation factor 15 and risk of major bleeding in atrial fibrillation: insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"190","author":"Hijazi","year":"2017","journal-title":"Am Heart J"},{"key":"2023072022174477700_euad200-B7","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1161\/CIRCULATIONAHA.114.011204","article-title":"Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"130","author":"Wallentin","year":"2014","journal-title":"Circulation"},{"key":"2023072022174477700_euad200-B8","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1161\/CIRCULATIONAHA.116.022802","article-title":"Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation","volume":"134","author":"Oldgren","year":"2016","journal-title":"Circulation"},{"key":"2023072022174477700_euad200-B9","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur Heart J"},{"key":"2023072022174477700_euad200-B10","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"2023072022174477700_euad200-B11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/eurheartj\/ehx584","article-title":"A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score","volume":"39","author":"Hijazi","year":"2018","journal-title":"Eur Heart J"},{"key":"2023072022174477700_euad200-B12","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1161\/CIRCULATIONAHA.120.053100","article-title":"Biomarker-based risk prediction with the ABC-AF scores in patients with atrial fibrillation not receiving oral anticoagulation","volume":"143","author":"Benz","year":"2021","journal-title":"Circulation"},{"key":"2023072022174477700_euad200-B13","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/hmg\/ddw012","article-title":"Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome","volume":"25","author":"Johansson","year":"2016","journal-title":"Hum Mol Genet"},{"key":"2023072022174477700_euad200-B14","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/europace\/euaa158","article-title":"Assessment of causality of natriuretic peptides and atrial fibrillation and heart failure: a Mendelian randomization study in the FINRISK cohort","volume":"22","author":"Geelhoed","year":"2020","journal-title":"Europace"},{"key":"2023072022174477700_euad200-B15","doi-asserted-by":"crossref","first-page":"e018984","DOI":"10.1161\/JAHA.120.018984","article-title":"Screening of multiple biomarkers associated with ischemic stroke in atrial fibrillation","volume":"9","author":"Hijazi","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2023072022174477700_euad200-B16","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cvr\/cvab262","article-title":"Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation","volume":"118","author":"Pol","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2023072022174477700_euad200-B17","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1111\/jth.15498","article-title":"Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation","volume":"19","author":"Siegbahn","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2023072022174477700_euad200-B18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for tie2 that disrupts in vivo angiogenesis","volume":"277","author":"Maisonpierre","year":"1997","journal-title":"Science"},{"key":"2023072022174477700_euad200-B19","doi-asserted-by":"crossref","first-page":"a006550","DOI":"10.1101\/cshperspect.a006650","article-title":"The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway","volume":"2","author":"Thurston","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2023072022174477700_euad200-B20","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2023072022174477700_euad200-B21","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2023072022174477700_euad200-B22","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2023072022174477700_euad200-B23","doi-asserted-by":"crossref","first-page":"9355","DOI":"10.1073\/pnas.90.20.9355","article-title":"Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system","volume":"90","author":"Sato","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023072022174477700_euad200-B24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrm2639","article-title":"Control of vascular morphogenesis and homeostasis through the angiopoietin-tie system","volume":"10","author":"Augustin","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2023072022174477700_euad200-B25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nm1351","article-title":"Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation","volume":"12","author":"Fiedler","year":"2006","journal-title":"Nat Med"},{"key":"2023072022174477700_euad200-B26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/cells8050471","article-title":"Role of angiopoietin-2 in vascular physiology and pathophysiology","volume":"8","author":"Akwii","year":"2019","journal-title":"Cells"},{"key":"2023072022174477700_euad200-B27","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1186\/cc9020","article-title":"Angiopoietin-2 is increased in sepsis and inversely associated with nitric oxide-dependent microvascular reactivity","volume":"14","author":"Davis","year":"2010","journal-title":"Crit Care"},{"key":"2023072022174477700_euad200-B28","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/thx.2007.087387","article-title":"Angiopoietin-2, permeability oedema, occurrence and severity of ALI\/ARDS in septic and non-septic critically ill patients","volume":"63","author":"van der Heijden","year":"2008","journal-title":"Thorax"},{"key":"2023072022174477700_euad200-B29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/07853890701779586","article-title":"Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension","volume":"40","author":"Patel","year":"2008","journal-title":"Ann Med"},{"key":"2023072022174477700_euad200-B30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2261-11-31","article-title":"Circulating angiopoietins-1 and -2, angiopoietin receptor tie-2 and vascular endothelial growth factor-a as biomarkers of acute myocardial infarction: a prospective nested case-control study","volume":"11","author":"Iribarren","year":"2011","journal-title":"BMC Cardiovasc Disord"},{"key":"2023072022174477700_euad200-B31","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ijcard.2012.03.120","article-title":"Increased serum angiopoietin-2 is associated with abdominal aortic aneurysm prevalence and cardiovascular mortality in older men","volume":"167","author":"Golledge","year":"2013","journal-title":"Int J Cardiol"},{"key":"2023072022174477700_euad200-B32","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/eurjhf\/hft117","article-title":"Circulating angiopoietin-2, its soluble receptor tie-2, and mortality in the general population","volume":"15","author":"Lorbeer","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2023072022174477700_euad200-B33","doi-asserted-by":"crossref","first-page":"e0135181","DOI":"10.1371\/journal.pone.0135181","article-title":"Angiopoietin-2 as a prognostic biomarker of major adverse cardiovascular events and all-cause mortality in chronic kidney disease","volume":"10","author":"Tsai","year":"2015","journal-title":"PLoS One"},{"key":"2023072022174477700_euad200-B34","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1055\/s-0038-1636543","article-title":"Angiopoietin-2 and survival in peripheral artery disease patients","volume":"118","author":"H\u00f6baus","year":"2018","journal-title":"Thromb Haemost"},{"key":"2023072022174477700_euad200-B35","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.jacc.2019.01.074","article-title":"Accelerating biomarker discovery through electronic health records, automated biobanking, and proteomics","volume":"73","author":"Wells","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023072022174477700_euad200-B36","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1161\/CIRCULATIONAHA.119.045158","article-title":"Prioritizing candidates of post-myocardial infarction heart failure using plasma proteomics and single-cell transcriptomics","volume":"142","author":"Chan","year":"2020","journal-title":"Circulation"},{"key":"2023072022174477700_euad200-B37","doi-asserted-by":"crossref","first-page":"e019168","DOI":"10.1161\/JAHA.120.019168","article-title":"Biomarkers of inflammation and risk of hospitalization for heart failure in patients with atrial fibrillation","volume":"10","author":"Benz","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2023072022174477700_euad200-B38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2022.03.009","article-title":"Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model","volume":"251","author":"Aulin","year":"2022","journal-title":"Am Heart J"},{"key":"2023072022174477700_euad200-B39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41569-022-00759-w","article-title":"Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology","volume":"20","author":"Dobrev","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2023072022174477700_euad200-B40","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1161\/CIRCRESAHA.120.316710","article-title":"Atrial myocyte NLRP3\/CAMKII nexus forms a substrate for postoperative atrial fibrillation","volume":"127","author":"Heijman","year":"2020","journal-title":"Circ Res"},{"key":"2023072022174477700_euad200-B41","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"2023072022174477700_euad200-B42","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-tie pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2023072022174477700_euad200-B43","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"key":"2023072022174477700_euad200-B44","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1538-7836.2012.04812.x","article-title":"High sensitivity cardiac troponin t and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation","volume":"10","author":"Rold\u00e1n","year":"2012","journal-title":"J Thromb Haemost"},{"key":"2023072022174477700_euad200-B45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.amjcard.2011.08.010","article-title":"Usefulness of high-sensitivity c-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] study)","volume":"109","author":"Hermida","year":"2012","journal-title":"Am J Cardiol"},{"key":"2023072022174477700_euad200-B46","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ahj.2015.09.018","article-title":"Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation","volume":"170","author":"Aulin","year":"2015","journal-title":"Am Heart J"},{"key":"2023072022174477700_euad200-B47","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1161\/CIRCULATIONAHA.112.000491","article-title":"Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study","volume":"128","author":"Marijon","year":"2013","journal-title":"Circulation"},{"key":"2023072022174477700_euad200-B48","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0140-6736(16)30968-0","article-title":"Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study","volume":"388","author":"Healey","year":"2016","journal-title":"Lancet"},{"key":"2023072022174477700_euad200-B49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1161\/01.CIR.0000079170.10579.DC","article-title":"N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies to Open occluded arteries (gusto)-IV substudy","volume":"108","author":"James","year":"2003","journal-title":"Circulation"},{"key":"2023072022174477700_euad200-B50","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa042330","article-title":"N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease","volume":"352","author":"Kragelund","year":"2005","journal-title":"N Engl J Med"},{"key":"2023072022174477700_euad200-B51","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2003-10-3685","article-title":"The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel\u2013Palade bodies","volume":"103","author":"Fiedler","year":"2004","journal-title":"Blood"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/advance-article-pdf\/doi\/10.1093\/europace\/euad200\/50899833\/euad200.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/7\/euad200\/50919649\/euad200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/7\/euad200\/50919649\/euad200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T22:18:33Z","timestamp":1689891513000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euad200\/7225558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euad200","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,7]]},"article-number":"euad200"}}